Novo Nordisk A/S holds the cleaner structural position, with profitability as the main driver and growth adding further support. Bayer Aktiengesellschaft does not offset that deficit through any equally strong structural edge elsewhere. In the market, Bayer Aktiengesellschaft carries the stronger setup — intact trend against Novo Nordisk A/S's broken trend. That leaves a split case: the structural lead stays with Novo Nordisk A/S, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.
The clearest separation starts in profitability, but growth adds another real layer to the result. The overall score gap is 23 points in favour of Novo Nordisk A/S.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. BAYN.DE and NOVO-B.CO share the same industry classification.
For a similarity-based comparison, see how Bayer Aktiengesellschaft and Novo Nordisk A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Novo Nordisk A/S is cheaper, but Bayer Aktiengesellschaft is still stronger.
Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.
Where BAYN.DE and NOVO-B.CO each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 35-point operating margin advantage.
On the market side, Bayer Aktiengesellschaft carries the stronger trend while Novo Nordisk A/S's trend has broken — the market setup does not confirm the structural advantage.
Profitability is the clearest driver, and growth also supports Novo Nordisk A/S's broader structural position.
Break down the BAYN.DE vs NOVO-B.CO comparison across all dimensions with the full interactive tool.
Explore how BAYN.DE and NOVO-B.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.